Pub Date : 1900-01-01DOI: 10.14744/ejmi.2022.51946
F. Tugrul
as space, equipment, and personnel. The present study tried to assess how the fear of hospitals and the pandemic measures affected the radiotherapy course of patients. Methods: The records of patients receiving active cancer therapy in the department of radiation oncology were retrospectively analyzed. Treatment delays before and after March 11, 2020, were recorded. Results: None of the 80 patients (0%) failed to complete radiotherapy before March 11, 2020, while 5 of 55 patients (9.1%) had radiotherapy cessation after the first COVID-19 case and the following restrictions in Turkey (p<0.01). There was no difference in treatment type between the groups; no difference between palliative and curative subgroups before and after the pandemic (p=0.22). There was no difference in overall survival between pre- and post-COVID-19 periods (p=0.35). Conclusion: However, some patients may not receive adequate diagnostic procedures during this period. The regulations to prevent the spread of the COVID-19 may harm specific patient populations such as radiotherapy patients. The non-specific rules and declarations confuse the patients and prevent them from accessing the treatment needed. In the case of pandemic regulations, government decisions may include special considerations for oncological patients. Abstract Cite This Article: Tugrul F, Beypinar I. The Radiotherapy Adherence of Patients in Time of COVID-19 Pandemic. EJMI 2022;6(4):512–516.
{"title":"The Radiotherapy Adherence of Patients in Time of COVID-19 Pandemic","authors":"F. Tugrul","doi":"10.14744/ejmi.2022.51946","DOIUrl":"https://doi.org/10.14744/ejmi.2022.51946","url":null,"abstract":"as space, equipment, and personnel. The present study tried to assess how the fear of hospitals and the pandemic measures affected the radiotherapy course of patients. Methods: The records of patients receiving active cancer therapy in the department of radiation oncology were retrospectively analyzed. Treatment delays before and after March 11, 2020, were recorded. Results: None of the 80 patients (0%) failed to complete radiotherapy before March 11, 2020, while 5 of 55 patients (9.1%) had radiotherapy cessation after the first COVID-19 case and the following restrictions in Turkey (p<0.01). There was no difference in treatment type between the groups; no difference between palliative and curative subgroups before and after the pandemic (p=0.22). There was no difference in overall survival between pre- and post-COVID-19 periods (p=0.35). Conclusion: However, some patients may not receive adequate diagnostic procedures during this period. The regulations to prevent the spread of the COVID-19 may harm specific patient populations such as radiotherapy patients. The non-specific rules and declarations confuse the patients and prevent them from accessing the treatment needed. In the case of pandemic regulations, government decisions may include special considerations for oncological patients. Abstract Cite This Article: Tugrul F, Beypinar I. The Radiotherapy Adherence of Patients in Time of COVID-19 Pandemic. EJMI 2022;6(4):512–516.","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"21 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124413407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.14744/ejmi.2021.24427
B. Oven
{"title":"Lifestyle behaviour after diagnosis of cancer","authors":"B. Oven","doi":"10.14744/ejmi.2021.24427","DOIUrl":"https://doi.org/10.14744/ejmi.2021.24427","url":null,"abstract":"","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129123673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.14744/ejmi.2023.59897
A. Ozveren
Objectives: Addition of trastuzumab and pertuzumab to neoadjuvant chemotherapy in Human epidermal growth factor receptor 2 (HER-2) positive breast cancer is the current clinical standard. We aimed to determine whether anthra-cycline-containing neoadjuvant chemotherapy yields beneficial effects alongside dual HER-2 blockade, and to assess cardiotoxicity with this treatment. Methods: Fifty-two patients with HER-2-positive breast cancer who received neoadjuvant chemotherapy were retrospectively evaluated at three tertiary health-care centers. The effects of chemotherapy regimen and several other factors such as age, stage, menopause status, lymph node positivity, and hormone receptor positivity on pathological complete response (pCR) were evaluated. Results: The mean age at diagnosis was 46±9 years. The pCR rate was similar between those with and without anthra-cycline-containing regimens (71.4% vs. 70%). Subgroup analyses also showed similar pCR values for those with negative and positive hormone receptors (64.7% vs. 74.3%), those with Ki67 levels <20% and >20% (60% vs. 73.8%), and when premenopausal patients were compared with postmenopausal patients (76.9% vs. 65.4%). Conclusion: It appears that adding anthracycline to dual HER-2 blockade for neoadjuvant therapy did not yield additional benefits in terms of pCR. Further studies are needed to assess anthracycline-containing regimens in patients who will use the neoadjuvant pertuzumab-trastuzumab combination.
{"title":"Chemotherapy Choice in Neoadjuvant Dual Her2 Blockade: Is it Really Essential to Add Anthracycline?","authors":"A. Ozveren","doi":"10.14744/ejmi.2023.59897","DOIUrl":"https://doi.org/10.14744/ejmi.2023.59897","url":null,"abstract":"Objectives: Addition of trastuzumab and pertuzumab to neoadjuvant chemotherapy in Human epidermal growth factor receptor 2 (HER-2) positive breast cancer is the current clinical standard. We aimed to determine whether anthra-cycline-containing neoadjuvant chemotherapy yields beneficial effects alongside dual HER-2 blockade, and to assess cardiotoxicity with this treatment. Methods: Fifty-two patients with HER-2-positive breast cancer who received neoadjuvant chemotherapy were retrospectively evaluated at three tertiary health-care centers. The effects of chemotherapy regimen and several other factors such as age, stage, menopause status, lymph node positivity, and hormone receptor positivity on pathological complete response (pCR) were evaluated. Results: The mean age at diagnosis was 46±9 years. The pCR rate was similar between those with and without anthra-cycline-containing regimens (71.4% vs. 70%). Subgroup analyses also showed similar pCR values for those with negative and positive hormone receptors (64.7% vs. 74.3%), those with Ki67 levels <20% and >20% (60% vs. 73.8%), and when premenopausal patients were compared with postmenopausal patients (76.9% vs. 65.4%). Conclusion: It appears that adding anthracycline to dual HER-2 blockade for neoadjuvant therapy did not yield additional benefits in terms of pCR. Further studies are needed to assess anthracycline-containing regimens in patients who will use the neoadjuvant pertuzumab-trastuzumab combination.","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"68 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131073830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.14744/ejmi.2023.86631
E. Kut
{"title":"Relationship Between Glucose-To-Lymphocyte, Albumin-To Alkaline Phosphatase and\u0000 Neutrophil-To-Lymphocyte Rat and Prognosis in Young Patients with Pancreatic\u0000 Cancer","authors":"E. Kut","doi":"10.14744/ejmi.2023.86631","DOIUrl":"https://doi.org/10.14744/ejmi.2023.86631","url":null,"abstract":"","PeriodicalId":310818,"journal":{"name":"Eurasian Journal of Medical Investigation","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131164495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}